BioSpace News Archive

Antibody Therapeutics Xchange – Europe 2025 takes place on 1st December at the Hilton Munich Airport Hotel, bringing together senior pharma and biotech leaders. The agenda covers target selection, lead optimization, formats & scaffolds, bi/multispecifics, and AI/ML. With roundtables, 1:1 meetings, and networking, this interactive event is designed to drive collaboration and innovation in antibody therapeutics.

Oligonucleotide Therapeutics Xchange – Europe 2025 will be held on 2nd December at the Hilton Munich Airport Hotel, bringing together senior pharma and biotech leaders to tackle challenges in therapeutic modalities, translational strategy, CMC/process development, and drug delivery. The program features expert-led roundtables, 1:1 meetings, presentations, and networking, creating an interactive environment to accelerate innovation in oligonucleotide therapeutics.

Megan Robertson is a life sciences attorney at the national health care and life sciences law firm Epstein Becker Green (EBG).

Jane Koo, PhD, head of regulatory at CTMC, is a regulatory expert with 20 years of experience in biologics and advanced therapies.

While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this week, experts told BioSpace the conference will also provide important insights into the therapeutic benefits of incretin therapies beyond weight loss.

After decades without much movement, a handful of new treatments for this rare autoimmune disease are now approved, and several companies, including argenx and Regeneron, have recently released promising late-stage trial results.

AstraZeneca in January also stopped its $610 million plans to construct a vaccine R&D and manufacturing site in the U.K.

Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.

A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study

CDER Director George Tidmarsh said on two separate events last week that he thought advisory committee meetings for specific drug applications were redundant, but then denied having said the agency would abandon them.